Kornimate/medical-research-clean huggingface dataset:
assess safety, efficacy and usability of application for atrial fibrillation vocal marker

Conditions: Atrial Fibrillation

Summary: voice assist arrhythmia monitoring (vaam) is an application running on smartphones and/or landline phones that performs vocal tests for the monitoring of abnormalities in the heart rhythm.

following icf signature and process and eligibility confirmation, subject will have a training session to assure correct application use. the subjects will be asked to pronounce few vowels 3 times a day to be evaluated by the application analysis algorithm at the patient natural environment. at the same time, a single lead ecg system will be recorded synchronously ecg for reference with the use of dedicated recording device

Eligibility criteria:
inclusion criteria: 1. female and male at age of ≥18 years and above. 2. all af types or medical history of cryptogenic stroke. 3. ability and willingness to sign an informed consent form exclusion criteria: 1. subjects with implanted cardiac defibrillators or pacemakers neurostimulators and/or body worn medical devices such as insulin pumps. 2. subjects diagnosed with any heart arrhythmias other than a-fib, except for pvc. 3. patient who underwent cardioversion or ablation in the last year and is in stable sinus rhythm. 4. women who are pregnant or breastfeeding (women of child-bearing potential must provide a declaration stating that they are not pregnant) 5. tremor or parkinson's disease 6. current hoarseness 7. barriers for communication and lack of capability to execute the handlings required for this study. 8. subjects who are currently enrolled in another clinical investigation. parallel enrollment to a non-interventional study is permitted.
augmented-reality based mirror therapy in stroke rehabilitation

Conditions: Stroke; Rehabilitation; Technology; Mirror Movement Therapy

Summary: in the proposed study, the investigators assumed that mirror therapy combined with augmented reality technology will provide a better treatment effects than traditional mirror therapy for the patients with unilateral stroke. the aim of the study is to examine the difference in the treatment effects among the combination of task-oriented training with either augmented reality based mirror therapy, mirror therapy or traditional occupational therapy on the upper extremity function and brain activity of the stroke patients.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of stroke with unilateral side involved; * a score of mini-mental state examination greater than 24 for proving higher mental function * time of onset \> 6 months before treatment begins; and * premorbid right-handedness. exclusion criteria: * severe vision impairment; * major cognitive-perceptual deficit; * other brain disease.
proton pump inhibitor versus histamine-2 receptor antagonist for the prevention of recurrent peptic ulcers

Conditions: Peptic Ulcer

Summary: whether pantoprazole versus famotidine for the prevention of recurrent peptic ulcers in thienopyridine users remains unclear.

the aims of the randomized double-blind comparison study are to compare the efficacy of proton pump inhibitor and h2 receptor antagonist for the prevention of recurrent peptic ulcers in thienopyridine users. we plan to enroll 334 thienopyridine (clopidogrel or ticlopidine) users without baseline gastroduodenal ulcer at initial endoscopy. the patients will be randomly assigned to receive either (1) pantoprazole (40 mg qd) or (2) famotidine (40 mg qd) for 6 months.the ulcer recurrence rate between the treatment groups will be compared.

Eligibility criteria:
inclusion criteria: * recent endoscopic examination (within 2 months) reveals normal appearance or erythematous patches only (without subepithelial hemorrhages, erosions or ulcers). * peptic ulcers (a mucosal break ³ 5 mm in diameter) have been documented by a previous endoscopic examination. * subjects have received thienopyridine therapy for at least two weeks. * requiring long-term anti-platelet therapy for ischemic cardiovascular diseases. exclusion criteria: * a history of gastric or duodenal surgery other than oversewing of a perforation. * subjects who are allergic to the study drugs. * requiring long-term treatment with non-steroidal anti-inflammatory drugs (nsaids), corticosteroids, aspirin, or anticoagulant agents. * pregnancy. * subjects who have active cancer, acute serious medical illness or terminal illness. * subjects who have gastroesophageal reflux disease.

Keywords: histamine-2 receptor antagonist proton pump inhibitor thienopyridine clopidogrel prevention
comparison of the effect of microchip and density gradient methods in intrauterine insemination cycles

Conditions: Infertility Unexplained; Infertility, Male

Summary: microfluidic chips are one of the methods of sperm separation to eliminate dna fragmentation in sperm. it is thought that the separation of sperm by centrifugation in the classical gradient density (percoll) method used in sperm separation in ivf and iui cycles leads to the increase of reactive oxygen radicals in sperm and this leads to sperm dna fragmentation. studies comparing percoll and microfluidic chip method in terms of sperm, embryo quality and pregnancy rates are limited. in this context, it is aimed to investigate the effect of percoll or microfluidic chip technology on the quality of sperms and embryos obtained with these sperms and their pregnancy rates prospectively.

the increase in infertility rate due to environmental and physiological conditions leads to an increase in the use of assisted reproductive techniques. isolation of living and morphologically normal live sperm is an integrated procedure in commonly used ivf / icsi(intracytoplasmic sperm injection) / iui(intrauterine insemination) procedures. although current iui procedures result in a successful pregnancy of around 10-15%, the process can be greatly compromised if the selected sperm is abnormal. microfluidic chips are one of the recommended sperm separation methods to eliminate dna fragmentation in sperm. it is thought that the separation of the sperm by centrifugation in the classical gradient density (percoll) method which is used in the separation of sperm in the iui cycles, causes the increase of reactive oxygen radicals in sperm and this leads to sperm dna fragmentation. studies comparing percoll and microfluidic chip method in terms of sperm, embryo quality and pregnancy rates are limited. in this context, it is aimed to investigate the effect of percoll or microfluidic chip technology on the quality of sperms and embryos obtained with these sperms and their pregnancy rates prospectively.

Eligibility criteria:
inclusion criteria: * apply to the infertility clinic due to unexplained infertility and mild male factor (total motile sperm count \>5 million) * volunteer exclusion criteria: * inadequate follicle development with medication * embryo does not have the appropriate quality for transfer * tubal pathology * total motile sperm count \< 5 million * refuse to participate in research

Keywords: microfluid chip gradient-density intrauterine insemination
evaluation of the gestational diabetes self-management education program and quality improvement plan

Conditions: Gestational Diabetes

Summary: the broad, long-term objectives are to generate and test hypotheses leading to theories that guide improved care of patients with gestational diabetes. the purpose of this chart review study is to evaluate the vanderbilt gestational diabetes self-management education program and quality improvement plan in optimizing metabolic control and improving health outcomes during pregnancy with gestational diabetes.


Eligibility criteria:
inclusion criteria: * women with gestational diabetes who are referred to and followed in the vanderbilt eskind diabetes clinic and are participants in the gestational diabetes educational program. exclusion criteria: * refusal of consent.

Keywords: gestational diabetes self-monitoring of blood glucose
a bioequivalence study of sch 530348 2.5 mg tablets (p06558)

Conditions: Acute Coronary Syndrome

Summary: the purpose of this study is determine if sch 530348 2.5 mg tablets containing a high percentage of drug as the free base are equivalent to tablets with the standard percentage when given to participants.


Eligibility criteria:
inclusion criteria: * body mass index (bmi) between 18 and 32, inclusive * clinical laboratory tests within normal limits * free of any clinically significant disease that would interfere with the study evaluations * screening 12-lead electrocardiogram (ecg) conduction intervals within gender-specific normal range * vital sign measurements within the following ranges: oral body temperature, 35.0°c to 37.5°c; systolic blood pressure, 90 to 140 mmhg; diastolic blood pressure, 45 to 90 mmhg; pulse rate, 40 to 100 beats per minute * female participants must be postmenopausal, surgically sterile, abstinent, or using medically accepted method of contraception for 3 months prior to the screening period, during the trial, and for 2 months after stopping the trial. non-vasectomized men must agree to use acceptable contraception or to abstain from sexual intercourse during the trial and for 3 months after stopping the medication exclusion criteria: * female participants who are pregnant, intend to become pregnant (within 3 months of ending the study), or are breastfeeding * history of coagulation disorder(s), thrombocytopenia, bleeding tendency, ulcers, or gastrointestinal bleeding * history of cardiac abnormalities including clinically relevant ecgs, frequent palpitations or syncopal episodes * any surgical or medical condition that might significantly alter the absorption, distribution, metabolism or excretion of any drug * history of any infectious disease within 4 weeks prior to drug administration * positive for hepatitis b surface antigen, hepatitis c antibodies or human immunodeficiency virus (hiv) * positive screen for drugs with a high potential for abuse * history of alcohol or drug abuse in the past 2 years * blood donation in the past 60 days * previous treatment with sch 530348 * currently participating in another clinical study or has participated in a clinical study within 30 days * demonstrated allergic reactions * smokes more than 10 cigarettes or equivalent tobacco use per day * history of malignancy * has received any protocol-defined treatment which could interfere with ability to participate in the trial
evaluation of trigeminal nerve blockade

Conditions: Mouth Abnormalities; Cleft Palate; Birth Defect

Summary: cleft palate repair requires high doses of opioids for pain control postop. an alternative approach is placement of nerve blocks in the pterygopalatine fossa bilaterally, blocking the maxillary nerve \& covering the entire midface. application of bilateral suprazygomatic maxillary nerve blockade of the infraorbital nerve may provide effective analgesia for cleft lip repair, improving time to oral intake, pain control and time to hospital discharge.

cleft palate is a common congenital anomaly for which surgical repair is indicated during early childhood. the surgical repair of cleft palate is very painful, and generally requires high doses of opioids for adequate pain control, placing children at risk for post-operative respiratory depression and airway obstruction. an alternative approach to post-operative analgesia for cleft palate repair is the placement of nerve blocks in the pterygopalatine fossa bilaterally, blocking the maxillary nerve and covering the entire mid-face. this randomized, double-blinded study will investigate the utility of maxillary nerve blockade in controlling post-operative pain, decreasing opioid requirements, improving post-operative oral food and drink intake, and decreasing hospital length-of-stay after cleft palate repair.

Eligibility criteria:
inclusion criteria: * patient presenting for palatoplasty for cleft palate only. * parent/guardian consents to participate * normal oral food and water intake before surgery * no underlying chronic pain condition exclusion criteria: * parent/guardian refuses to consent * patient requires revision surgery on the palate * patient requires surgery in addition to palatoplasty, including, but not limited to pharyngeal flap or soft palate lengthening procedures. * any underlying chronic pain condition * presence of any other factor which, at the discretion of any member of the study team, makes the patient a poor candidate for block placement. * presence of any other factor which, at the discretion of any member of the study team, makes the patient a poor candidate for research participation. * history of pierre robin sequence * planned or anticipated need for any type of artificial airway post-op
the effectiveness of idazoxan in treating trd

Conditions: Major Depressive Disorder

Summary: assessing the effectiveness of idazoxan as a treatment for depressive patients who did not respond to treatment with ssri


Eligibility criteria:
inclusion criteria: * mdd patients * did not respond to at least one treatment of 4-6 weeks of ssri in adequate dose * in or out patients exclusion criteria: * psychotic symptoms
lavender aromasticks for pain control

Conditions: Pain Perception; Patient Satisfaction

Summary: the purpose of this randomized pilot study is to collect preliminary data on the impacts of lavender essential oil aromatherapy on the patient-reported quality of pain management provided for the vascular surgery patient population. the investigators hypothesize that individuals who use a lavender aromastick as a part of their pain management plan will report improved perceptions of the quality of their pain management as measured by the revised american pain society patient outcome questionnaire (aps-poq-r). subjects will be randomized to the control (empty aromastick) and intervention group (aromastick infused with lavender oil), and will use this device as an addition to their pain management plan. additionally, this pilot study will allow the researchers to evaluate the feasibility of a larger randomized control trial, assess the validity of the survey tool, and collect feedback from patients on the acceptability of the aromatherapy intervention as a complementary therapy during their hospital stay.


Eligibility criteria:
inclusion criteria: 1. subjects 18 and over admitted to the vascular surgery service line on the heart and vascular progressive care unit (hvpcu) 2. not cognitively impaired 3. able to perform teach-back of the education regarding safe use of the aromastick 4. able to demonstrate use of the numeric pain rating scale (nprs), as evidenced by their ability to answer the initial nprs question on the adult admission ii form used to admit all patients to the hospital 5. english is the primary language, as identified by the adult admission ii form exclusion criteria: 1. subjects who are unable to consent themselves 2. subjects who cannot provide teach-back on the safe use of the aromastick 3. subjects unable to use the nprs to rate their pain 4. research team member and/or bedside nurse assess that subject has a cognitive deficit that would prohibit safe use of the aromastick 5. subjects on suicide precautions 6. pregnant subjects 7. prisoners 8. individuals under age 18 9. subjects with a current plan to use personal aromatherapy devices during their inpatient stay 10. subjects with known lavender allergy
exploring the clinical application value of caix-targeted pet imaging in renal cancer patients

Conditions: Tumor; Carbonic Anhydrase IX

Summary: to evaluate the efficacy of targeted caix-specific probe pet imaging in the diagnosis and staging of kidney cancer, as well as to assess its role in prognosis prediction and treatment evaluation for kidney cancer.

images will be analyzed by at least two physicians with extensive experience in nuclear medicine and radiological diagnostics. regions of interest (rois) will be delineated for the lesion tissues to measure volume and suv values. the interpreted pet/ct imaging results will be compared to the corresponding histopathological results of the lesions (obtained through biopsy or surgery) and will be used as the reference standard. we will employ mcnemar's test to compare the sensitivity, specificity, accuracy, positive predictive value, and negative predictive value of targeted caix pet/ct imaging and enhanced ct in primary tumors, metastatic lymph nodes, and distant metastatic lesions.

Eligibility criteria:
inclusion criteria: 1. voluntary participation with the patient or their legal representative able to sign the informed consent form. 2. adult patients (age between 18 and 75 years), regardless of gender. 3. patients with clinically suspected or confirmed primary kidney cancer (supporting evidence includes imaging data and histopathological examination; specific case types include clear cell carcinoma, papillary renal cell carcinoma, and chromophobe renal cell carcinoma) who agree to undergo histopathological examination (if not already performed prior to imaging). 4. patients must have undergone enhanced ct, with the enhanced ct examination conducted within 2 weeks prior to enrollment. 5. ecog performance status score of 0-3. 6. laboratory parameters must meet the following criteria: 1. alt and ast must not exceed 3 times the upper limit of normal; bun and creatinine must not exceed 1.5 times the upper limit of normal. 2. hematological parameters: 2 x 10\^9/l ≤ wbc ≤ 2 x 10\^10/l, plt ≥ 80 x 10\^9/l, hb ≥ 80 g/l. 7. willing and able to comply with follow-up visits, treatment plans, and related laboratory examinations. exclusion criteria: 1. pregnant or breastfeeding patients (all women of childbearing age must undergo pregnancy testing during the screening phase, such as a urine pregnancy test or blood hcg test, to confirm their pregnancy status). 2. patients or their legal representatives who are unable or unwilling to sign the informed consent form. 3. acute systemic diseases and electrolyte imbalances. 4. patients unable to complete the pet/ct examination (including those unable to lie flat, those with claustrophobia, radiophobia, etc.). 5. researchers believe that the patient has poor compliance or has other factors making them unsuitable for participation in this study.

Keywords: pet caix renal cancer diagnosis
efficacy of inhaled cannabis for acute migraine treatment

Conditions: Migraine; Cannabis; THC; CBD

Summary: this crossover study will evaluate 3 different treatments of vaporized cannabis (thc, thc/cbd mix, and cbd) and vaporized placebo cannabis for the acute treatment of migraine.

in this double-blind, randomized, crossover trial, subjects will treat 4 separate migraine attacks with 4 different treatments. inhaled cannabis will be administered using a portable vaporization system (mighty medic; storz \& bickel) based on a validated storz \& bickel system and using a standardized inhalation approach. subjects will self-administer inhaled cannabis as early as possible in the course of a migraine (see procedure), taking 4 puffs of 1) thc, 2) thc/cbd mix, 3) cbd, or 4) placebo. patients will treat each of the 4 distinct migraine attacks with a different cannabis sample. outcomes measured will include pain freedom and pain relief as well as presence or absence of photophobia, phonophobia, and nausea at 1 hour, 2 hours (primary outcome), 24 hours, and 48 hours.

Eligibility criteria:
inclusion criteria: * age ≥ 21 and ≤ 65 * able to communicate in english * migraine, with or without aura, in its episodic or chronic manifestations, as per the international headache society (ihs) classification international classification of headache disorders (ichd-3) criteria (section 1.1, 1.2, 1.3).(48) * ability to provide informed consent and complete website questionnaires in english * agrees not to use cannabis outside of the study during participation in the study * agrees not to use opioids or barbiturates during participation in the study * agrees not to drive a motor vehicle within 4 hours following last use of inhaled cannabis during participation in the study exclusion criteria: * positive urine drug test for thc, barbiturates, opioids, oxycodone, or methadone prior to enrollment * pregnancy * breastfeeding * prisoner * known cognitive impairment * institutionalized * current moderate-severe or severe depression * current or past history of bipolar depression, schizophrenia, or psychosis * current or past history of cannabis, alcohol, opioid, or amphetamine abuse or other substance use disorder at the discretion of the research team * active pulmonary disease class iv heart failure, cirrhosis, or other severe medical illnesses at the discretion of the research team. * allergy or past adverse effects or negative past experiences from cannabis

Keywords: migraine cannabis thc cbd
the beijing childhood eye study

Conditions: Myopia

Summary: axial myopia has emerged as the leading cause of irreversible vision loss in east asia, driven by its progression to sight-threatening complications including myopic macular degeneration, retinal detachment, open-angle glaucoma, and other complications. in the current study, we aim to observe the natural course of the development , progression, and its associated factors in children

this is a prospective epidemiological cohort study, recruiting students in grades 1-3 in primary school for myopia. through stratified cluster random sampling, among aii the primary schools in dongcheng district, beijing, schools were stratified into key and ordinary schools, with 2 schools randomly selected from each stratum. a prospective study cohort comprising 3,667 subjects was established. all study subjects completed a standard questionnaire and underwent routine ophthalmic examinations. follow-up assessments will be conducted regularly to monitor changes in refractive errors and fundus indicators. informed consent, approved by the ethics committee of beijing tongren hospital, was obtained from all participants.

Eligibility criteria:
inclusion criteria: 1) currently enrolled students in grades 1-3 of the selected primary schools, in good health, with normal ocular appearance. 2) no ocular diseases, no strabismus, ocular trauma, or history of intraocular surgery, with unaided visual acuity of 20/20 or better. 3) parental and student consent to participate in the survey and signed informed consent form. exclusion criteria: 1) not currently enrolled in grades 1-3 of a primary school. 2) students with pre-existing strabismus, other ocular diseases, or a history of ocular surgery at baseline, or those allergic to cycloplegic eyedrops. 3) students unable to continue studying at their current school for more than three years from the baseline, including those who transfer to another school or withdraw from the study; 4) parental or student disagreement with participation in the survey.

Keywords: myopia child axial length refractive error